Sun Pharmaceutical Industries Limited is set to present 14 abstracts at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled from March 27-31 in Denver, Colorado. This presentation underscores the company’s leadership in dermatology and immunology, highlighting its commitment to advancing treatments for conditions such as psoriasis, alopecia areata, and acne.
Ahmad Naim, MD, Senior Vice President and North American Chief Medical Officer at Sun Pharma, emphasised the importance of these presentations, stating that they reflect the company’s dedication to meaningful scientific advancements that translate into clinically significant outcomes for patients. The presentations will cover a range of topics, including clinical efficacy, safety, and real-world performance of therapies.
Key presentations include data on ILUMYA® (tildrakizumab-asmn), which showed sustained efficacy and safety in a Phase 3b study for moderate-to-severe psoriasis affecting the nails over 52 weeks. The data also demonstrated ILUMYA’s holistic disease management capabilities across diverse patient populations worldwide. ILUMYA is approved for moderate-to-severe plaque psoriasis in several countries, including the U.S., Australia, Japan, and Europe, where it is marketed as ILUMETRI®.
Additionally, pooled data from the THRIVE-AA1 and THRIVE-AA2 pivotal trials of LEQSELVI™ (deuruxolitinib) in severe alopecia areata showed significant scalp hair regrowth as early as Week 8 and Week 12, with continuous improvements over time. A survey revealed gaps in perceptions of disease burden and treatment goals, highlighting the need for better communication in patient-centered care.
The company will also present findings from an open-label, 52-week study on WINLEVI® (clascoterone cream 1%), which demonstrated significant reduction in facial sebum production and acne severity. This reinforces WINLEVI’s role in targeting the androgen-sebum pathway and its potential in multimodal acne therapies.
Sun Pharma’s booth at the AAD Annual Meeting will offer interactive experiences for clinicians, showcasing the company’s comprehensive dermatology and immunology portfolio.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).